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Original Research

Association Between Chronic Kidney Disease–Mineral
Bone Disease (CKD-MBD) and Cognition in Children:
Chronic Kidney Disease in Children (CKiD) Study
Jennifer S. Yokoyama, Mina Matsuda-Abedini, Michelle R. Denburg, Juhi Kumar,
Bradley A. Warady, Susan L. Furth, Stephen R. Hooper, Anthony A. Portale, and Farzana Perwad
Rationale & Objective: Chronic kidney disease
(CKD) in children is associated with cognitive
dysfunction that affects school performance and
quality of life. The relationship between CKD–mineral
and bone disorder and cognitive function in children
is unknown.
Study Design: Observational study.
Participants: 702 children enrolled in the Chronic
Kidney Disease in Children (CKiD) Study.
Predictors: Plasma ﬁbroblast growth factor 23
(FGF-23), parathyroid hormone (PTH), calcium,
phosphorus, 25 hydroxyvitamin D (25[OH]D), and
1,25 dihydroxyvitamin D (1,25[OH]2D).
Outcomes: Neurocognitive tests of intelligence,
academic achievement, and executive functions.
Analytical Approach: Linear regression models to
analyze the cross-sectional associations between
log2FGF-23, 25(OH)D, 1,25(OH)2D, PTH, calcium,
and phosphorus z scores and the cognitive test
scores of interest after adjustment for demographics,
blood pressure, proteinuria, and kidney function.
Results: At baseline, median age was 12 (95% CI,
8.3, 15.2) years and estimated glomerular ﬁltration
rate was 54 (40.5, 67.8) mL/min/1.73 m2. In fully

C

adjusted analyses, 25(OH)D, 1,25(OH)2D, PTH,
calcium, and phosphorus z scores did not associate
with cognitive test scores. In fully adjusted analyses,
log2FGF-23 was associated with abnormal test
scores for attention regulation (P < 0.05); specifically, Conners’ Continuous Performance Test II
Errors of Omission (β = 2.3 [1.0, 3.6]), Variability
(β=1.4 [0.4, −2.4]), and Hit Reaction Time (β = 1.3
[0.2, 2.4]). Children in the highest FGF-23 tertile
group had 7% and 9% greater cognitive risk
for Hit Reaction Time and Errors of Omission
compared with those in the lowest tertile,
respectively. In fully adjusted analyses, higher FGF23 tertile was associated with increased cognitive
risk (P < 0.05) for Errors of Omission (β = 0.4
[0.1, 0.7]) and Hit Reaction Time (β = 0.4 [0.1, 0.7]).
Limitations: The study does not assess the
cumulative effects of FGF-23 excess on cognitive
function over time. Within-population stratiﬁed
analyses were not performed due to limited
sample size.
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Conclusions: In children with CKD, higher plasma
FGF-23 level is associated with lower performance
in targeted tests of executive function, speciﬁcally
attention regulation, independent of glomerular
ﬁltration rate.

hronic kidney disease (CKD) in children is associated
with higher morbidity and mortality than seen in the
general pediatric population.1-3 Despite advances in the
care of children with CKD, such as improved nutrition,
anemia management, avoidance of aluminum-based
phosphate binders, adequate dialysis, and timely kidney
transplantation, emerging studies show that children with
CKD remain at risk for cognitive dysfunction, particularly
in the areas of attention regulation and associated executive
functions.4 Cognitive dysfunction can lead to poor school
performance and lower quality of life. Lower performance
has been reported in measures of academic achievement,
such as numerical operations, compared with chronological age expectations.5,6
In prior studies of children from the Chronic Kidney
Disease in Children (CKiD) cohort, median cognitive
function was within the range of normal values; however,
21% to 40% of participants scored at least 1 standard deviation (SD) below the normative mean on measures of
intelligence quotient (IQ), achievement, attention, and
executive functions.6,7 Similarly, in adults who had
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childhood-onset CKD, verbal and nonverbal IQ were lower
than in their unaffected peers, and educational attainment
and employment rates were lower compared with those
without CKD.8,9 In adult-onset CKD, the prevalence of
severe cognitive dysfunction in patients receiving dialysis
is higher than the prevalence of dementia reported in
community-based populations.10 Collectively, these
studies show that children and adults with CKD are at
increased risk for neurocognitive deficits that in turn can
negatively affect their educational performance, disease
self-management, occupational outcomes, and healthrelated quality of life. However, there is a paucity of
literature on risk factors that increase the likelihood of
cognitive dysfunction in CKD.
Fibroblast growth factor 23 (FGF-23) is a bone-derived
circulating hormone that is critical for maintaining phosphorus and vitamin D homeostasis and thereby skeletal
mineralization.11-13 In CKD, plasma FGF-23 level increases
early and is associated with disordered mineral metabolism,14,15 CKD progression,16-18 left ventricular hypertrophy,19,20 poor cardiovascular health, and mortality.21-24
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PLAIN-LANGUAGE SUMMARY
Cognitive impairment is a known complication of
chronic kidney disease (CKD) in children. However,
little is known about risk factors that might increase the
likelihood of cognitive impairment in CKD. The present
study provides the first large-scale evaluation of associations between biomarkers of bone and mineral
metabolism and cognitive function in children with
predialysis CKD. Higher plasma fibroblast growth factor
23 (FGF-23) concentrations were independently associated with poor performance on cognitive function
tests, specifically measures of attention regulation. Our
study is the first to provide evidence for an association
between plasma FGF-23 level and complications
involving the central nervous system in children with
CKD.

In preclinical studies, FGF-23 was shown to directly
regulate neural networks in the hippocampus, an important region for learning, memory, and attention regulation.25 In adults with CKD, associations between
circulating FGF-23 levels and neurologic complications,
particularly impaired cognitive function, were examined,
but the findings are controversial.26-28 In children, FGF-23
protein is detected in the cerebrospinal fluid29 but no prior
studies have examined the relationship between levels of
FGF-23 or other biomarkers of bone and mineral metabolism and cognitive function in children with and
without CKD.
In the present study, we address this gap in the pediatric
literature by testing the hypothesis that higher plasma FGF23 level is associated with poor performance on specific
measures of cognitive function in children with CKD. We
also examine associations between other biomarkers of
bone and mineral metabolism and cognitive function in
this population.
METHODS
The CKiD Study is a prospective observational study that
enrolled 891 children aged 1 to 16 years with estimated
glomerular filtration rates (eGFRs) between 30 and
90 mL/min/1.73 m2 at 54 centers across North America
from January 2005 to March 2015.7,30-32 The study
design, methods, and exclusion criteria have been
described previously.30 The study was approved by the
UCSF Institutional Review Board #18-25119, and all
participants provided informed consent.
Participants
For the present cross-sectional analysis, we included
702 children aged 6 to 16 years in whom baseline
measurement of plasma FGF-23, mineral metabolism
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biomarkers, and neurocognitive testing were performed
3 to 6 months after enrollment.
Neurocognitive Tests
A battery of tests was carefully administered to assess key
areas of cognitive functions (Table S1). All tests were
standardized, age normed, age appropriate, and administered to each study participant by a trained psychologist
or trained technician supervised by the psychologist at
each site.7,33 We selected specific cognitive tests to: (1)
align with literature pertaining to cognition in mild to
moderate CKD4-7 and (2) have strong psychometric
properties that included age-based normative data. These
measures include the Wechsler Abbreviated Scales of
Intelligence-2 (WASI-2; intellectual function); Wechsler
Individual Achievement Test-II-Abbreviated (WIAT-II-A;
Total Achievement [academic achievement]); Conners’
Continuous Performance Test-II (CPT-II; Errors of
Omission, Errors of Commission, Hit Reaction Time,
Detectability, and Variability [selective attention, impulsivity, and attention regulation]); Digit Span Backwards
from the age-appropriate Wechsler Intelligence Scale
(verbal working memory); parent ratings on the Behavior
Rating Inventory of Executive Functions (BRIEF; executive
functions) summary scores of Behavior Regulation Index
(BRI), Metacognition Index, and Global Executive
Composite.
Biochemistries
We measured plasma C-terminal FGF-23 using a secondgeneration enzyme-linked immunosorbent assay (Immutopics Int); inter- and intra-assay coefficients of variation
were 11.5% and 5.7%, respectively.15 Median plasma FGF23 value in healthy children of comparable age was 57
(2.5th and 97.5th percentiles, 17 and 101) RU/mL. Serum
vitamin D metabolites were measured using Heartland
Assays as described.15 All other biochemistry test results
were determined at the CKiD Central Biochemistry Laboratory, University of Rochester.32 Kidney function was
determined by eGFR calculations using the full CKiD
(eGFRCKiDfull ) equation based on serum creatinine, cystatin C, and serum urea nitrogen levels; height; and sex.34
eGFR data were collected at all study visits compared with
iohexol GFR, which was measured at select time points
only. eGFRCKiDfull closely approximated measured iohexol
GFR to describe relationships between risk factors and CKD
progression in this pediatric population35 and is the
preferred equation for research purposes using this pediatric cohort.
Statistical Analysis
All analyses presented are cross-sectional, using plasma
FGF-23, serum 25-hydroxyvitamin D (25[OH]D), 1,25dihydroxyvitamin D (1,25[OH]2D), parathyroid hormone (PTH), calcium, and phosphorus levels obtained at
baseline as the primary exposure. Values were expressed
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Table 1. Participant Characteristics in Overall CKiD Cohort and by FGF-23 Tertile
Characteristic
N
Demographics
Age, y
Female sex
White
African American
Hispanic ethnicity
Kidney
Iohexol GFR, mL/min/1.73 m2a
Glomerular CKD
Nonglomerular CKD
CKD duration, y
Laboratory
Urine protein-creatinine
ratio, mg/ga
Serum phosphorus, mg/dLa
Serum 25(OH)D, ng/mL
Serum 1,25(OH)2D, pg/mLa
Serum calcium, mg/dL
Serum iPTH, pg/mLa
Plasma FGF-23, RU/mL
Medication Use
Antihypertensive
Phosphate binders
Active vitamin D

Overall Cohort
702

FGF-23 Tertile 1
(≤87.5 RU/m L)
235

FGF-23 Tertile 2
(87.6-147.4 RU/m L)
233

FGF-23 Tertile 3
(≥147.5 RU/m L)
234

11.8 [8.3, 15.2]
270 (38%)
477 (68%)
107 (15%)
94 (14%)

11.5 [8.5, 15.3]
82 (35%)
161 (69%)
29 (12%)
37 (16%)

11.7 [8.3, 15.1]
85 (36%)
161 (69%)
38 (16%)
29 (13%)

12.6 [8.1, 15.2]
103 (44%)
155 (66%)
40 (17%)
28 (12%)

54 [40.5, 67.8]
223 (32%)
479 (68%)
8.3 ± 4.9

64 [51.4, 76.9]
76 (32%)
159 (68%)
8.0 ± 4.8

55 [45.2, 66.1]
66 (28%)
167 (72%)
8.9 ± 4.9

41 [32.3, 55.4]
81 (35%)
153 (65%)
8.1 ± 5.0

0.003 [0.001, 0.009]

0.002 [0.001, 0.006]

0.002 [0.001, 0.006]

0.006 [0.002, .018]

4.5 ± 0.8
27.9 ± 11.9
34.1 ± 12.7
9.5 ± 0.6
62.4 ± 72.9
111.4 [77.8, 174.8]

4.3 ± 0.7
28.4 ± 10.1
36.5 ± 11.9
9.5 ± 0.5
40.4 ± 25.0
67.9 [55.4, 77.9]

4.4 ± 0.7
28.6 ± 12.0
35.9 ± 12.8
9.5 ± 0.5
55.7 ± 36.9
111.5 [98.8, 127]

4.7 ± 0.9
26.8 ± 13.3
29.9 ± 12.4
9.4 ± 0.7
92.4 ± 113.7
223.2 [174.8, 308.2]

458 (65%)
117 (17%)
190 (27%)

157 (67%)
30 (13%)
30 (13%)

146 (63%)
30(13%)
57 (25%)

155 (66%)
57 (24%)
103 (44%)

Note: Data presented as mean ± standard deviation, median [25th, 75th percentile], or number (percent).
Abbreviations: 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; CKD, chronic kidney disease; CKiD, Chronic Kidney Disease in Children; FGF23, ﬁbroblast growth factor 23; GFR, glomerular ﬁltration rate; iPTH, intact parathyroid hormone.
a
P ≤ 0.001 by tertile.

either as a continuous or a categorical variable using tertiles. Values of FGF-23 were log2-transformed to satisfy
normality assumptions. Values of phosphorus for each
participant were expressed as a z score relative to agematched values in healthy children.36
The primary outcome of interest was neurocognitive
test performance; test values for each assessment were
compared with age-appropriate norms from the general
population and expressed as a standard score. Cognitive
risk was defined as a standard score ≥ 1 SD below the test
mean (categorical outcome). Higher cognitive test scores
indicate better performance for WASI-2, WIAT-II-A, and
Digit Span Backwards. Higher scores indicate worse performance for CPT-II tests, BRI, Metacognition Index, and
Global Executive Composite.
We tested for differences in the distribution of each of
the cognitive test standard scores across tertiles of plasma
FGF-23 using the Kruskal-Wallis test and examined the
unadjusted associations between cognitive test standard
scores and log2 plasma FGF-23 (representing per
doubling) using Pearson correlation. We also tested for
differences in the prevalence of cognitive risk for each
cognitive test across tertiles of FGF-23 using 2-tailed χ 2 test
and examined the associations between cognitive risk and
log2 FGF-23 using 1-way analysis of variance. When 1 or
400

more cognitive function tests was associated with either
log2FGF-23 or FGF-23 tertiles at a significance level < 0.1,
we performed multivariable regression analyses as
described next for all measures within the specific cognitive domain of interest.
We used linear regression models to examine the association between log2FGF-23, 25(OH)D, 1,25(OH)2D,
PTH, calcium, and phosphorus z score values and cognitive
test score(s) of interest. Model 1 was unadjusted; model 2
was adjusted for sex, age, race, and Hispanic ethnicity
(yes/no); model 3 was additionally adjusted for eGFR and
urine protein-creatinine ratio (UPCR, yes/no ≥ 2); and
model 4 was additionally adjusted for hypertension
(defined as systolic blood pressure [BP] ≥ 95th percentile).
In separate analyses, we used multivariable logistic
regression to quantify the effect of tertiles of FGF-23 on
the odds of cognitive risk; models were adjusted for the
same covariates as listed. All analyses were performed using Stata 10/MP (StataCorp LP).
RESULTS
Cohort Characteristics
Characteristics of the 702 participants, overall and by tertile of plasma FGF-23, are summarized in Table 1. Median
Kidney Med Vol 2 | Iss 4 | July/August 2020
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Table 2. Neurocognitive Test Scores in CKiD Cohort
Measure
Intellectual Functioning
WASI-2 IQ
Academic Achievement
WIAT II-A Total
Achievement
Attention Regulation
CPT-II Omission
CPT-II Commission
CPT-II VAR
CPT-II HIT REACT
CPT-II DETECT
Executive Functioning
Digit Span Backward
BRIEF-P BRI
MI
GEC

Mean

SD

Conﬁdence Interval
(5th-95th percentile)

Cognitive Risk
Threshold

N

Percent
at Risk

97.2

15.7

71-122

≤85

590

23%

95.6

18.1

65-126

≤85

289

29%

52.8
51.6
51.1
49.0
52.0

14.4
11.0
11.2
12.0
10.3

42-81
33-66
35-69
32-73
33-65

≥60
≥60
≥60
≥60
≥60

537
538
538
538
538

18%
26%
25%
17%
23%

9.2
52.9
55.0
54.4

2.9
11.7
11.6
11.7

4-13
38-76
38-76
38-76

≤7
≥60
≥60
≥60

269
585
582
662

27%
26%
32%
31%

Note: Cognitive risk is deﬁned as scores ≥ 1 SD below expected performance for age. Mean and SD of normative values for cognitive test scores provided the basis
for establishing a risk category. IQ calculated from WASI-2: mean ± SD, 100 ± 15 (higher scores are better), ACHIEVE; achievement total scaled score derived from
Word Reading, Numerical Operations, and Spelling from WIAT-II-A: mean ± SD, 100 ± 15 (higher scores are better), CPT-II scores depending on age: COMMISSION, HIT REACT, OMISSION, VAR, DETECT: mean ± SD, 50 ± 10 (higher scores are worse), Digits Span Backwards is a subset of Digit Span from the ageappropriate Wechsler Intelligence Scale for Children-IV Test: mean ± SD, 19 ± 3, higher scores are better. BRIEF-P all scores: BRI, MI, and GEC: mean ± SD,
50 ± 10 (higher scores are worse for BRI, MI, and GEC).
Abbreviations: BRI, Behavior Regulation Index scaled score from BRIEF; BRIEF-P, Behavior Rating Inventory of Executive Functions, parents rating; CKiD, Chronic
Kidney Disease in Children; COMMISSION, Commission T Score; CPT-II, Conners’ Continuous Performance Test-II; DETECT, Detectability; GEC, Global Executive
Composite scaled score from BRIEF derived from BRI and MI; HIT REACT, Hit Reaction time; IQ, intelligence quotient; MI, Metacognition Index scaled score from
BRIEF; OMISSION, Omission T Score; SD, standard deviation; VAR, Variability; WASI-2, Wechsler Abbreviated Scales of Intelligence-2; WIAT-II-A, Wechsler Individual Achievement Test-II-Abbreviated.

age was 12 years, 38% were female, 68% were white, and
15% were African American, with 14% reporting Hispanic
ethnicity. Median eGFR was 54.2 (interquartile range, 4068) mL/min/1.73 m2. CKD was caused by nonglomerular
disease in 68% of participants, 65% reported taking antihypertensive medications, 27% took active vitamin D sterols, and 17% took phosphate binders. Median plasma
FGF-23 concentration was 111 (interquartile range, 78175) RU/mL. Compared with the lowest FGF-23 tertile
(≤87.5 RU/mL), participants in the highest tertile (≥147.5
RU/mL) had lower eGFRs and were more likely to have
higher UPCR, phosphorus, and PTH values and lower
1,25(OH)2D concentrations (Table 1).
Measures of Cognitive Function and Cognitive Risk
Assessment
As a group, children with CKD performed near the expected
cognitive score for their age (Table 2). WASI-2 IQ score
(mean ± SD, 97.2 ± 15.6) was in the normal range. WIATII-A Total Achievement score (mean ± SD, 95.6 ± 18.1) also
was within the normal range. Mean values for measures of
attention regulation (ie, CPT-II Errors of Omission, Errors of
Commission, Hit Reaction Time, Detectability, and Variability) were age appropriate. Parental ratings of executive
functions revealed few overall problems, with the 3 major
BRIEF indexes (BRI, Metacognition Index, and Global Executive Composite) reflecting age-appropriate functioning.
Kidney Med Vol 2 | Iss 4 | July/August 2020

We then determined the percentage of children with
CKD who were at cognitive risk (Table 2). When analyzed
as a group, cognitive test scores in children with CKD were
within the normal range. However, when individual patients were examined, a large percentage (18%-33%) of
children were categorized as being at risk for cognitive
dysfunction (ie, ≥1 SD below the test mean) for a given
cognitive test. Specifically, the percentage of children at
cognitive risk was 23% for IQ, 29% for total achievement,
18% to 26% for attention regulation, and 26 to 33% on
parent ratings of executive functioning. Compared with
the distribution in otherwise healthy children (ie, w16%),
these data demonstrate that a greater percentage than expected of children with mild to moderate CKD are at risk
for cognitive dysfunction.
Associations of FGF-23 Concentrations With
Cognitive Test Scores
Unadjusted associations between plasma FGF-23 levels and
cognitive test scores are shown in Table S2. Among the
cognitive domains examined, scores for the following tests
showed associations (P < 0.1) by either FGF-23 tertile,
log2FGF-23, or both: CPT-II tests for Errors of Omissions,
a measure of selective attention; Variability and Hit Reaction Time, measures of attention regulation; Detectability,
a measure of overall attention; and WIAT II-A Total
Achievement score.
401
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Table 3. Adjusted Associations Between FGF-23 Level and Cognitive Tests for Attention Regulation

Cognitive Function
Tests
CPT-II Omissions
CPT-II Commissions
CPT-II
VAR
CPT-II HIT REACT
CPT-II DETECT

Association With log2FGF-23

Association With FGF-23
Tertile 2 vs 1

Association With FGF-23
Tertile 3 vs 1

Coefﬁcient (β)
(95% CI)
2.3 (1.0 to 3.6)
0.1 (−0.9 to 1.2)
1.4 (0.4 to 2.4)

P
0.001a
0.8
0.009a

Coefﬁcient (β)
(95% CI)
−0.2 (−3.2 to 2.7)
1.3 (−1.1 to 3.7)
0.3 (−2.1 to 2.6)

P
0.9
0.3
0.8

Coefﬁcient (β)
(95% CI)
5.8 (2.6 to 9.0)
−0.3 (−2.9 to 2.3)
3.0 (0.5 to 5.5)

P
<0.001a
0.8
0.02a

1.3 (0.2 to 2.4)
0.7 (−0.2 to 1.7)

0.02a
0.1

−1.0 (−3.5 to 1.5)
0.6 (−1.7 to 2.8)

0.4
0.5

4.8 (2.1 to 7.5)
1.5 (−0.9 to 3.9)

0.001a
0.2

Note: Plasma FGF-23 concentrations were either log base 2 transformed (representing doubling of FGF-23) or expressed as tertiles (β coefﬁcient and P for highest vs
lowest tertile). Outcome of interest is CPT-II scores depending on age: OMISSION. COMMISSION, VAR, HIT REACT, and DETECT. Coefﬁcient represents β value of
FGF-23 effect after accounting for all other variables in the model. Covariates: age, sex, race, Hispanic, estimated glomerular ﬁltration rate, urine protein-creatinine
ratio ≥ 2, and hypertension (≥95th percentile systolic blood pressure). N = 490 for CPT-II OMISSIONS, N = 491 for CPT-II Commissions, VAR, HITREACT, and
DETECT.
Abbreviations: CI, conﬁdence interval of T score; COMMISSION, Commission T Score; CPT-II, Conners’ Continuous Performance Test-II; DETECT, Detectability;
FGF-23, ﬁbroblast growth factor 23; HIT REACT, Hit Reaction time; OMISSION, Omission T Score; VAR, Variability.
a
Statistically signiﬁcant.

Multivariable Regression Analysis of Associations
of FGF-23 With Cognitive Function
The association between log2FGF-23 and FGF-23 tertile for
cognitive test scores showing an unadjusted association
(P < 0.1) with FGF-23 level was further examined using
multivariable linear regression; the fully adjusted model
included age, sex, race, eGFR, UPCR, and systolic hypertension (Tables 3, S2, and S3). We observed that log2 FGF23 level remained significantly associated with poorer
scores for 3 of the 5 measures of attention regulation,
specifically CPT-II Errors of Omission, Variability, and Hit
Reaction Time in the fully adjusted model (Table 3).
Interestingly, the strength of the association between
plasma FGF-23 level and CPT-II Errors of Omission,
Variability, and Hit Reaction Time was stronger in model 4
compared with models 2 and 3 after adjusting for eGFR,
UPCR, and hypertension (Table S3). Among the covariates,
younger age was associated with lower performance for
CPT-II Errors of Omission, Variability, and Hit Reaction
Time and nonwhite race was associated with poor performance for CPT-II Errors of Omission. CPT-II Detectability, CPT-II Errors of Commission, and WIAT II-A scores
were not associated with FGF-23 levels in fully adjusted
analyses. The associations between plasma FGF-23 levels
and test scores for CPT-II Errors of Omission, Variability,
and Hit Reaction Time were also significant in the fully
adjusted model when plasma FGF-23 level was expressed
as tertiles (Table 3).
Relationship Between FGF-23 Concentrations and
Cognitive Risk
The prevalence of cognitive risk for each cognitive test
according to FGF-23 tertiles is shown in Table 4. In the
unadjusted analysis, cognitive risk showed associations
(P < 0.1) either by FGF-23 tertile or log2FGF-23 or both
with the following tests: WASI-2 IQ, CPT-II Errors of
Omission and Hit Reaction Time, and the BRIEF BRI
summary score. In the fully adjusted model, higher
402

FGF-23 tertile was significantly associated with increased
cognitive risk for 2 of the 5 measures of attention regulation (CPT-II Errors of Omission and Hit Reaction
Time; Tables 4 and S4). Compared with children with
FGF-23 levels ≤ 87.5 RU/mL, children with FGF-23
levels ≥ 147.5 RU/mL had 9% (26% vs 17%) and 6%
(22% vs 16%) higher rates of cognitive risk on CPT-II
Errors of Omission and Hit Reaction Time, respectively.
In pairwise comparisons for these 2 cognitive measures,
there is a statistically significant difference between tertiles
2 and 3 (P < 0.01) but not between tertiles 1 and 2.
WASI-2 IQ, a measure of intellectual functioning, and
summary scores from the BRIEF test, measures of executive
function, were not associated with FGF-23 levels in fully
adjusted analyses. The associations between plasma FGF-23
levels and cognitive risk for CPT-II Errors of Omission
were also significant in the fully adjusted model when
expressed as FGF-23 level doubling (Table 4).
Relationship Between Mineral Metabolites and
Cognitive Function
To assess the specificity of the association of FGF-23 levels
with cognitive dysfunction, we examined whether levels
of other markers of mineral metabolism were associated
with differences in cognitive test performance in children
with CKD. In the fully adjusted analyses, 25(OH)D,
1,25(OH)2D, PTH, calcium, and phosphorus z scores did
not associate with any of the cognitive test scores listed in
Table 2. There was a trend toward significance for associations between phosphorus z scores and CPT-II Errors of
Omission (P = 0.08) and between serum 25(OH)D levels
and CPT-II Errors of Commission (P = 0.06) in the fully
adjusted analyses.

DISCUSSION
In the present cohort of 702 children with predialysis
CKD, higher plasma FGF-23 levels were independently
Kidney Med Vol 2 | Iss 4 | July/August 2020
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Table 4. Adjusted Associations Between FGF-23 Levels and Cognitive Risk for Attention Regulation

Cognitive Function
Tests
CPT-II Omissions
CPT-II Commissions
CPT-II VAR
CPT-II HIT REACT
CPT-II DETECT

Association With log2FGF-23

Association With FGF-23
Tertile 2 vs 1

Association With FGF-23
Tertile 3 vs 1

Coefﬁcient (β)
(95% CI)
0.4 (0.1 to 0.6)
−0.09 (−0.3 to −0.1)
0.2 (−0.03 to 0.4)
0.2 (−0.07 to 0.4)
0.1 (−0.08 to 0.4)

Coefﬁcient (β)
(95% CI)
−0.06 (−0.2 to 0.8)
0.03 (−0.5 to 0.5)
−0.2 (−0.7 to 0.3)
0.03 (−0.6 to 0.6)
0.2 (−0.4 to 0.7)

Coefﬁcient (β)
(95% CI)
0.8 (0.2 to 1.4)
−0.2 (−0.7 to 0.4)
0.4 (−0.2 to 0.9)
0.8 (0.2 to 1.5)
0.4 (−0.2 to 0.9)

P
0.002a
0.5
0.08
0.2
0.2

P
0.8
0.9
0.4
0.9
0.7

P
0.01a
0.5
0.2
0.008a
0.2

Note: Plasma FGF-23 concentrations were either log base 2 transformed (representing doubling of FGF-23) or expressed as tertiles (β coefﬁcient and P for highest vs
lowest tertile). Outcome of interest is cognitive risk deﬁned as a score > 1 standard deviation below age-speciﬁc mean on the CPT-II scores depending on age:
OMISSION, COMMISSION, VAR, HIT REACT, and DETECT. Coefﬁcient represents β value of FGF-23 effect after accounting for all other variables in the model.
Covariates: age, sex, race, Hispanic, estimated glomerular ﬁltration rate, urine protein-creatinine ratio ≥ 2, and hypertension (≥95th percentile systolic blood pressure).
N = 490 for CPT-II Omissions, N = 491 for CPT-II Commissions, VAR, HITREACT and DETECT.
Abbreviations: CI, conﬁdence interval of z score; COMMISSION, Commission T Score; CPT-II, Conners’ Continuous Performance Test-II; DETECT, Detectability;
FGF-23, ﬁbroblast growth factor 23; HIT REACT, Hit Reaction time; OMISSION, Omission T Score; VAR, Variability.
a
Statistically signiﬁcant.

associated with poor performance in 3 of the 5 cognitive
tests for selective attention and attention regulation. Risk
for poor performance (defined as ≥1 SD below test mean)
on CPT-II Errors of Omission was 1.5 times greater in
participants with FGF-23 levels ≥ 147.5 RU/mL compared
with those with FGF-23 levels ≤ 87.5 RU/mL. We also
observed a significant association between log2FGF-23 and
FGF-23 tertiles with other measures of attention, specifically CPT-II Hit Reaction Time and Variability, but not for
CPT-II Errors of Commission and Detectability. The associations remained significant after adjustment for known
risk factors for cognitive dysfunction, including eGFR,
systolic BP, and proteinuria.4 More importantly, these associations were specific for FGF-23 levels because no association was found for levels of other markers of
CKD–mineral and bone disorders, including vitamin D
metabolites, PTH, calcium, and phosphorus.
In a child with CKD, cognitive deficits can have a major
adverse effect over their lifetime on educational achievement, disease self-management, occupational outcome,
and health-related quality of life.8-10 The substantial improvements in the care of CKD realized over the last 4
decades are predicted to be neuroprotective. However,
emerging studies show that some children with CKD
remain at risk for cognitive dysfunction.4-7,37 The present
study provides the first large-scale evaluation of associations between CKD–mineral and bone disorders and
cognitive function. As a group, children with mild to
moderate CKD in our study tested within age-appropriate
norms for IQ, academic achievement, and attention/executive functions. However, when individual patients were
examined, a substantial proportion of children were at risk
for cognitive dysfunction; the prevalence of risk ranged
from w18% to 33% for any given cognitive test. These
findings were consistent with prior reports.4
In our prior study, we observed that GFR and proteinuria were associated with poor performance on some
but not all of the neurocognitive tests examined.7 Specifically, iohexol-based GFR was a significant predictor of
Kidney Med Vol 2 | Iss 4 | July/August 2020

academic achievement skills, with each 10 mL/min/
1.73 m2 increase in iohexol-based GFR being associated
with a 1.4-point increase in achievement skills, but not
with any of the other cognitive tests examined. Proteinuria
was a significant predictor for poor performance on Verbal
IQ and Full-Scale IQ, but not for Performance IQ, and for
poor performance on CPT-II Errors of Omission, but not
for Errors of Commission.7 These findings suggest that
there may be a particular threshold for kidney disease
burden before one can observe cognitive dysfunction in a
specific domain, and the adverse effects of early CKD on
cognition can only be delineated with more precise measurements of the respective cognitive domains (intelligence, achievement, attention dimension, and executive
functions).
There is emerging evidence that hypertension adversely
affects cognitive function in children with and without
CKD.38 Children with early life primary hypertension
performed poorly on cognitive tests, particularly in the
domains of attention, working memory, and executive
function. Learning disability is several-fold higher in
children with hypertension compared with children with
prehypertension, suggesting that there is a real-world
impact of poor neurocognitive test performance in youth
with primary hypertension.39 In the CKiD cohort, children
with elevated systolic and diastolic BPs had worse scores on
the WASI compared with normotensive children.33 Participants with systolic visit-to-visit BP variability in the
upper tertile scored lower on the Delis-Kaplan Executive
Function System Verbal Category Switching test compared
with participants with BP variability in the lower tertile,
suggesting that the difficulties with executive function may
be related in part to increased visit-to-visit BP variability.31
In our regression models, we adjusted for elevated systolic
BP (Tables 3 and 4) and diastolic BP, but neither covariate
alone or in combination attenuated the associations between plasma FGF-23 levels and cognitive test performance, suggesting that mechanisms by which FGF-23
levels affect cognition are independent of blood pressure.
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Moreover, unlike FGF-23, elevated BP was not associated
with CPT-II cognitive tests in the CKiD cohort.
Observations from CKiD were corroborated in a recent
meta-analysis that assessed cognitive and educational outcomes in children with CKD.40 In that analysis, cognitive
deficits were more prevalent than in the general population; the specific patterns of deficit were evident for
attention, memory, and executive function domains.
Regarding attention regulation, children with CKD showed
problems with attention regulation when assessed using
CPT-II Errors of Omission and Commission tests.40 In the
present study, we found that level of FGF-23, a marker of
disordered bone and mineral metabolism, is a strong independent predictor of poor attention regulation, with
plasma FGF-23 levels ≥ 147.5 RU/mL associated with 50%
greater risk for poor attention regulation in children with
mild to moderate CKD.
To our knowledge, to date our study is the first to
examine the associations between FGF-23 levels and
cognitive function using a targeted array of neurocognitive
tests in a large representative cohort of children with CKD.
In adults with CKD, whether FGF-23 level associates with
cognitive function is unclear.26-28 Further, risk factors for
cognitive dysfunction in children may be distinctly
different from those in adults, thus limiting comparisons.
In 2 studies of adult patients with and without CKD, no
association between FGF-23 level and incident cognitive
dysfunction was observed.26,28 However, cognitive testing
was limited to telephone interviews, and direct assessment
of cognitive function was not performed. In contrast, in a
smaller cohort of adults receiving dialysis, high plasma
FGF-23 concentrations associated with memory deficits
when individuals were assessed using a detailed battery of
neurocognitive tests.27 In our study, we found statistically
significant relationships between higher FGF-23 levels and
poor selective attention and attention regulation more
generally—functions that can be strongly associated with
working memory and short-term recall.
Whether FGF-23 contributes directly or indirectly to
biological mechanisms underlying impaired cognitive
function in children with CKD remains to be determined.
There is a paucity of literature on the actions of FGF-23 in
the central nervous system. FGF-23 has been detected in
cerebrospinal fluid in humans and in rodent brain.25,29,41
In vitro cultures of murine hippocampal cells demonstrate
that FGF-23 modulates neuron morphology and synaptic
density,25 potentially making such functions as attention
and memory vulnerable to FGF-23 excess. However, the
biological effect of such regulation of hippocampal neural
networks by FGF-23 is yet to be investigated. Of interest,
the role of the hippocampus in attention regulation was
recently investigated; magnetic resonance imaging performed in a large cohort of children with attention deficithyperactivity disorder showed reduced brain volumes in
the amygdala, hippocampus, and other areas known to
control attention-related behavior.42 The present study
demonstrated that high FGF-23 concentrations in children
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with CKD associate with poor attention regulation, findings that support the hypothesis that FGF-23 has an
important biological role in the central nervous system.
Our study has some limitations. First, we did not
measure serum klotho in our cohort. Klotho is a cofactor
for renal actions of FGF-23 to inhibit phosphate transport
and 1,25(OH)2D synthesis.43 Higher soluble klotho concentrations were recently shown to associate with better
cognitive function in preclinical studies and in the aging
population.44 Currently, reliable assays to measure klotho
in children with CKD are not available and normal reference ranges in children are not well established. Second,
further studies are needed to determine whether FGF-23
level associates with cognitive dysfunction in CKD in
other population cohorts and to assess the effects of cumulative FGF-23 excess on cognitive function over time.
Should our findings be replicated in both cross-sectional
and longitudinal investigations, this would suggest that
higher FGF-23 level is a biological marker for cognitive
dysfunction in children.
SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Table S1: List of cognitive function tests
Table S2: Neurocognitive test scores by FGF-23 tertiles and unadjusted association with log2FGF-23
Table S3: Neurocognitive test scores and adjusted associations
between FGF-23 and cognitive tests for attention regulation, all
models
Table S4: Proportion of children at cognitive risk according to FGF23 tertile and unadjusted association with log2FGF-23
Table S5: Adjusted associations between FGF-23 and cognitive risk
for attention regulation, all models

ARTICLE INFORMATION
Authors’ Full Names and Academic Degrees: Jennifer S.
Yokoyama, PhD, Mina Matsuda-Abedini, MD, Michelle R. Denburg,
MD, Juhi Kumar, MD, Bradley A. Warady, MD, Susan L. Furth, MD,
Stephen R. Hooper, PhD, Anthony A. Portale, MD, and Farzana
Perwad, MD.
Authors’ Afﬁliations: Department of Neurology, Memory and Aging
Center (JSY), and Department of Radiology and Biomedical Imaging
(JSY), University of California, San Francisco, San Francisco, CA;
Division of Nephrology, University of Toronto, The Hospital for Sick
Children, Toronto, ON, Canada (MM-A); Children’s Hospital of
Philadelphia, Division of Nephrology, Perelman School of Medicine,
University of Pennsylvania, Philadelphia, PA (MRD, SLF); Division
of Nephrology, Weill Cornell Medical College, New York, NY (JK);
Division of Nephrology, Children’s Mercy Kansas City, Kansas City,
MO (BAW); Department of Allied Health Sciences, School of
Medicine, University of North Carolina at Chapel Hill, Chapel Hill,
NC (SRH); and Division of Nephrology, Department of Pediatrics,
University of California, San Francisco, San Francisco, CA (AAP,
FP).
Address for Correspondence: Farzana Perwad, MD, University of
California, San Francisco, 550 16th St, San Francisco, CA
94158. E-mail: farzana.perwad@ucsf.edu
Authors’ Contributions: Study design: FP, AAP, MM-A; data
analysis/interpretation: JSY, FP; data collection: MD, JK, BAW,
Kidney Med Vol 2 | Iss 4 | July/August 2020

Yokoyama et al.
SLF, SRH; supervision/mentorship: BAW, SLF. Each author
contributed important intellectual content during manuscript
drafting or revision and accepts accountability for the overall work
by ensuring that questions pertaining to the accuracy or integrity
of any portion of the work are appropriately investigated and
resolved.
Support: Primary support for data analysis was provided by the
National Institutes of Health/National Institute of Aging K01
AG049152 (Dr Yokoyama), Larry L. Hillblom Foundation 2016-A005-SUP (Dr Yokoyama), Tau Consortium (Dr Yokoyama), Blueﬁeld
Project to Cure FTD (Dr Yokoyama), and John Douglas French
Alzheimer’s Foundation (Dr Yokoyama). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Financial Disclosure: The authors declare that they have no
relevant ﬁnancial interests.
Acknowledgements: We thank all participants for contributions to
this research. Data in this manuscript were collected by the CKiD
prospective cohort study with clinical coordinating centers
(Principal Investigators) at Children’s Mercy Hospital and the
University of Missouri–Kansas City (Bradley A. Warady, MD) and
Children’s Hospital of Philadelphia (Susan L. Furth, MD, PhD),
Central Biochemistry Laboratory (George Schwartz, MD) at the
University of Rochester Medical Center, and data coordinating
center (Alvaro Mu~
noz, PhD) at the Johns Hopkins Bloomberg
School of Public Health. CKiD is funded by the National Institute
of Diabetes and Digestive and Kidney Diseases, with additional
funding from the National Institute of Child Health and Human
Development and the National Heart, Lung, and Blood Institute
(U01-DK-66143, U01-DK-66174, U01DK-082194, U01-DK66116). The CKID website is located at http://www.statepi.jhsph.
edu/ckid.
Peer Review: Received October 22, 2019. Evaluated by 1 external
peer reviewer, with direct editorial input from the Statistical Editor, an
Associate Editor, and the Editor-in-Chief. Accepted in revised form
March 16, 2020.

REFERENCES
1. McDonald SP, Craig JC. Long-term survival of children with
end-stage renal disease. N Engl J Med. 2004;350:2654-2662.
2. Saran R, Li Y, Robinson B, et al. US Renal Data System
2014 Annual Data Report: epidemiology of kidney disease in
the United States. J Am Soc Nephrol. 2015;66:Svii, S1-Svii, 305.
3. Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR.
Growth failure, risk of hospitalization and death for children
with end-stage renal disease. Pediatr Nephrol. 2002;17:
450-455.
4. Gipson DS, Hooper SR, Duquette PJ, et al. Memory and executive functions in pediatric chronic kidney disease. Child
Neuropsychol. 2006;12:391-405.
5. Gerson AC, Butler R, Moxey-Mims M, et al. Neurocognitive
outcomes in children with chronic kidney disease: current
ﬁndings and contemporary endeavors. Ment Retard Dev Disabil Res Rev. 2006;12:208-215.
6. Harshman LA, Johnson RJ, Matheson MB, et al. Academic
achievement in children with chronic kidney disease: a report
from the CKiD cohort. Pediatr Nephrol. 2019;34:689-696.
7. Hooper SR, Gerson AC, Butler RW, et al. Neurocognitive
functioning of children and adolescents with mild-to-moderate
chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:
1824-1830.
8. Bartosh SM, Leverson G, Robillard D, Sollinger HW. Long-term
outcomes in pediatric renal transplant recipients who survive
into adulthood. Transplantation. 2003;76:1195-1200.
Kidney Med Vol 2 | Iss 4 | July/August 2020

9. Groothoff JW, Grootenhuis M, Dommerholt A, Gruppen MP,
Offringa M, Heymans HS. Impaired cognition and schooling in
adults with end stage renal disease since childhood. Arch Dis
Child. 2002;87:380-385.
10. Kalirao P, Pederson S, Foley RN, et al. Cognitive impairment in
peritoneal dialysis patients. J Am Soc Nephrol. 2011;57:612-620.
11. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced
osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500-6505.
12. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent
regulator of vitamin D metabolism and phosphate homeostasis.
J Bone Miner Res. 2004;19:429-435.
13. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast
growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol.
2007;293:F1577-F1583.
14. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23
is elevated before parathyroid hormone and phosphate in
chronic kidney disease. Kidney Int. 2011;79:1370-1378.
15. Portale AA, Wolf M, Juppner H, et al. Disordered FGF23 and
mineral metabolism in children with CKD. Clin J Am Soc
Nephrol. 2014;9:344-353.
16. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23
(FGF23) predicts progression of chronic kidney disease: the
Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc
Nephrol. 2007;18:2600-2608.
17. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M. Mineral
metabolites and CKD progression in African Americans. J Am
Soc Nephrol. 2013;24:125-135.
18. Portale AA, Wolf MS, Messinger S, et al. Fibroblast growth
factor 23 and risk of CKD progression in children. Clin J Am
Soc Nephrol. 2016;11:1989-1998.
19. Mitsnefes MM, Betoko A, Schneider MF, et al. FGF23 and left
ventricular hypertrophy in children with chronic kidney disease.
Clin J Am Soc Nephrol. 2018;13:45-52.
20. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-4408.
21. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and
risks of mortality and end-stage renal disease in patients with
chronic kidney disease. JAMA. 2011;305:2432-2439.
22. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth
factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.
23. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of ﬁbroblast growth factor 23 and uncarboxylated matrix
Gla protein with mortality in coronary artery disease: the Heart
and Soul Study. Ann Intern Med. 2010;152:640-648.
24. Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23
and cardiovascular events in CKD. J Am Soc Nephrol.
2014;25:349-360.
25. Hensel N, Schon A, Konen T, et al. Fibroblast growth factor 23
signaling in hippocampal cells: impact on neuronal morphology
and synaptic density. J Neurochem. 2016;137:756-769.
26. Panwar B, Judd SE, Howard VJ, Jenny NS, Wadley VG,
Gutierrez OM. Vitamin D, ﬁbroblast growth factor 23 and incident cognitive impairment: ﬁndings from the REGARDS Study.
PLoS One. 2016;11:e0165671.
27. Drew DA, Tighiouart H, Scott TM, et al. FGF-23 and cognitive
performance in hemodialysis patients. Hemodial Int. 2014;18:
78-86.
28. Jovanovich AJ, Chonchol M, Brady CB, et al. 25-Vitamin D, 1,
25-vitamin D, parathyroid hormone, ﬁbroblast growth factor-23
and cognitive function in men with advanced CKD: a veteran
population. Clin Nephrol. 2014;82:S1-S4.

405

Yokoyama et al.
29. Kunert SK, Hartmann H, Haffner D, Leifheit-Nestler M. Klotho
and ﬁbroblast growth factor 23 in cerebrospinal ﬂuid in children. J Bone Miner Metab. 2017;35:215-226.
30. Furth SL, Cole SR, Moxey-Mims M, et al. Design and methods
of the Chronic Kidney Disease in Children (CKiD) prospective
cohort study. Clin J Am Soc Nephrol. 2006;1:1006-1015.
31. Lande MB, Mendley SR, Matheson MB, et al. Association of
blood pressure variability and neurocognition in children with
chronic kidney disease. Pediatr Nephrol. 2016;31:2137-2144.
32. Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of
rapid progression of glomerular and nonglomerular kidney
disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort. Am J Kidney Dis. 2015;65:
878-888.
33. Lande MB, Gerson AC, Hooper SR, et al. Casual blood pressure and neurocognitive function in children with chronic kidney
disease: a report of the children with chronic kidney disease
cohort study. Clin J Am Soc Nephrol. 2011;6:1831-1837.
34. Schwartz GJ, Schneider MF, Maier PS, et al. Improved equations estimating GFR in children with chronic kidney disease
using an immunonephelometric determination of cystatin C.
Kidney Int. 2012;82:445-453.
35. Ng DK, Schwartz GJ, Warady BA, Furth SL, Munoz A. Relationships of measured iohexol GFR and estimated GFR with
CKD-related biomarkers in children and adolescents. Am J
Kidney Dis. 2017;70:397-405.
36. Lockitch G, Halstead AC, Wadsworth L, Quigley G, Reston L,
Jacobson B. Age- and sex-speciﬁc pediatric reference intervals

406

37.

38.

39.

40.

41.

42.

43.

44.

and correlations for zinc, copper, selenium, iron, vitamins A and
E, and related proteins. Clin Chem. 1988;34:1625-1628.
Ruebner RL, Laney N, Kim JY, et al. Neurocognitive dysfunction
in children, adolescents, and young adults with CKD. J Am Soc
Nephrol. 2016;67:567-575.
Lande MB, Kupferman JC. Blood pressure and cognitive
function in children and adolescents. Hypertension. 2019;73:
532-540.
Adams HR, Szilagyi PG, Gebhardt L, Lande MB. Learning
and attention problems among children with pediatric primary
hypertension. Pediatrics. 2010;126:e1425-e1429.
Chen K, Didsbury M, van ZA, et al. Neurocognitive and
educational outcomes in children and adolescents with CKD: a
systematic review and meta-analysis. Clin J Am Soc Nephrol.
2018;13:387-397.
Yamashita T, Yoshioka M, Itoh N. Identiﬁcation of a novel
ﬁbroblast growth factor, FGF-23, preferentially expressed in the
ventrolateral thalamic nucleus of the brain. Biochem Biophys
Res Commun. 2000;277:494-498.
Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with attention deﬁcit hyperactivity disorder in children and adults: a cross-sectional megaanalysis. Lancet Psychiatry. 2017;4:310-319.
Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a speciﬁc receptor for FGF23. Nature. 2006;444:770-774.
Dubal DB, Yokoyama JS, Zhu L, et al. Life extension factor
klotho enhances cognition. Cell Rep. 2014;7:1065-1076.

Kidney Med Vol 2 | Iss 4 | July/August 2020

